用APX-115准NADPH氧化酶:抑制血小板激活和血栓反应
Joara Jang1, Hyunseong Yu1, Eun Bee Oh1
1College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Antioxidants & redox signaling
|April 4, 2025
概括
新型泛NOX抑制剂APX-115通过减少NADPH氧化酶衍生反应性氧物种 (ROS) 来有效抑制血小板激活和血栓形成. 这项研究强调了APX-115作为一个有前途的抗血小板和抗血栓治疗剂.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 来自NADPH氧化酶 (NOX) 的活性氧物种 (ROS) 对于血小板激活和血栓形成至关重要.
- 准NOX介导的ROS为血栓性疾病提供了潜在的治疗策略.
研究的目的:
- 研究泛NOX抑制剂APX-115在抑制血小板激活和血栓形成方面的疗效.
- 阐明APX-115影响ROS产生和血小板信号通路的分子机制.
主要方法:
- 在原刺激的人类血小板中评估了细胞内和细胞外ROS的产生.
- 评估了血小板聚合,P-选择因暴露,ATP释放和整合素αIIbβ3激活.
- 分析了信号通路,包括氨酸激酶,PKC,调动,MAPK和血栓素生产.
- 在老鼠模型中研究了剪切和动脉血栓形成和动脉血栓形成.
主要成果:
- APX-115显著抑制了ROS的产生,血小板聚合,P-选择因暴露和ATP的释放.
- APX-115保留了蛋白质氨酸酸酶活性,减少了下游信号和调动.
- APX-115抑制了整合素激活,血栓素生成和酸暴露,减少了血栓形成而不增加出血时间.
结论:
- APX-115有效地抑制NOX介导的ROS产生,血小板激活和血栓形成.
- APX-115显示出作为一种新型抗血小板和抗血栓剂的潜力,用于治疗心血管疾病.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
420
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
420
01:22Formation of the Platelet Plug
3.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
124
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
124
01:23Antihypertensive Drugs: Vasodilators
440
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
440
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
104
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
104